




International Journal of Medicine and Pharmaceutical Research

Journal Home Page: www.pharmaresearchlibrary.com/ijmpr



Research Article

Open Access

Design and Development of Pantoprazole Floating In-Situ Gel

Bhargavi Tambali*, Venkata Ramana Bachu, Venkata Badarinath Atluri

Dr. K. V. Subba Reddy Institute of Pharmacy, Kurnool, Andhra Pradesh, India – 518218

ABSTRACT

The aim of this investigation is to formulate and evaluate floating in-situ gel of Pantoprazole solution by using polymer dispersion technique. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H⁺, K⁺)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H⁺, K⁺)-ATPase results in a duration of anti secretory effect that persists longer hours for all doses tested (20 mg to 120 mg). The metabolism of pantoprazole is independent of the route of administration, with a half-life of approximately 1.1 hours. However in patients with a mutation in the gene encoding the CYP2C19 enzyme, the half-life may be up to 3 hours. Pantoprazole is selected as a model drug for this investigation because its oral dose is 20-120 mg varied short biological half life (1-3 hrs) and extensive first pass metabolism. 40 mg for sustained release tablets effect lasts for usually 6-8 hrs according to the survey. To improve the oral bioavailability, reduce the frequency of administration pantoprazole was designed as solution converts into gel in the presence of gastric solution (pH 1-2), which was designed by using sodium alginate as sustaining polymer, calcium carbonate as cross linking agent and floating behavior by the help of calcium carbonate and citric acid by dispersion technique and subjected to in vitro evaluation studies

Keywords: Pantoprazole, proton pump inhibitor, Bioavailability, evaluation

ARTICLE INFO

CONTENTS

1. Introduction. 111
2. Materials and Methods. 112
3. Results and discussion. 113
4. Conclusion 114
5. References. 116

Article History: Received 02 June 2017, Accepted 07 July 2017, Available Online 10 August 2017

*Corresponding Author

Bhargavi Tambali
Dr. K. V. Subba Reddy Institute of
Pharmacy, Kurnool,
Andhra Pradesh, India – 518218
Manuscript ID: IJMPR3440



PAPER-QR CODE

Citation: Bhargavi Tambali, et al. Design and development of pantoprazole Floating in-situ gel. *Int. J. Med. Pharm. Res.*, 2017, 5(4): 111-117.

Copyright© 2017 Bhargavi Tambali, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Peptic ulcers are open craters or sores that develop in the inner lining (mucosa) of the stomach or the duodenum (the International Journal of Medicine and Pharmaceutical Research

first section of the small intestine). A coating of mucus and other chemicals normally shield the stomach and duodenum

from digesting themselves. When these protective mechanisms are disrupted, powerful digestive acids can erode into the lining of these organs and cause peptic ulcers [1]. There are many new ulcer treatments available, depending on the type and cause, of the ulcer in question. Surgery is rarely necessary. Two of the most common causes must be identified and addressed if present, H. Pylori infection and NSAID use. A new approach is to try to combine advantages of both solutions and gels, such as accuracy and ease of administration of the former and prolonged residence time of the latter. Thus, in situ hydrogels can be instilled as eye drops and undergo an immediate gelation when in contact with the eye. In situ-forming hydrogels are liquid upon instillation and undergo phase transition in the ocular cul-de-sac to form viscoelastic gel and this provides a response to environmental change. [2]. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H⁺, K⁺)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H⁺, K⁺)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg). [3]

2. Materials and Methods

Materials: Pantoprazole is a purchased from yarrow chem. Products, Mumbai. All the other materials and chemicals are of analytical grade.

Methods:

Preformulation Studies [4]:

Determination of UV Absorbance Maxima of Pantoprazole: The standard stock solution was used to determine the max of (0.1 N HCl, pH 1.2) was used as blank for the study. The spectrum was taken between the UV range of 200-400nm. The highest peak obtained from the spectrum analysis was taken as max for Pantoprazole.

Identification of Drug by FTIR- Compatibility of Pantoprazole with gelling agent and other excipients was established by infrared spectral analysis IR Spectral analysis of samples (Ranitidine hydrochloride, Sodium Citrate, Sodium alginate, calcium carbonate, sorbitol) was carried out to investigate the changes in chemical composition of the drug.

Preparation of Formulations

Preparation of Pantoprazole in-situ gelling solutions – The polymeric dispersion was prepared by dispersing required quantity of gums and polymers in water using a magnetic stirrer and allowing it to swell overnight. SA (sodium alginate) Solutions were prepared in distilled water by heating to 60°C under continuous stirring. After cooling below 40°C ingredients including drug, gelling agent and other excipients were weighed accurately and formulations were prepared as per the table 1. The resulting six formulations (F1-F6) were finally stored in amber coloured bottles until further use [5].

Evaluation Studies:

Physical Appearance and pH: All the prepared sodium alginate based **in-situ** solution were checked for their

clarity and the type of the solution. After administration of the prepared solution in (0.1N HCL, pH 1.2) also checked the time required for gel formation and type of gel formed. The pH was measured in each of the solution of sodium alginate based **in-situ** solution using a calibrated digital pH meter at 27°C. The measurement of pH of each data was in triplicate [6].

Viscosity of in situ gelling solutions

The viscosity of formulations was determined by a Brookfield viscometer DV-III (Brookfield, USA) using spindle number 21 with cup and bob setting at 50 rpm [7].

Floating behavior

The floating ability of the prepared formulations was evaluated in (0.1N HCl, pH 1.2) Solution. The floating time of the prepared formulation took to emerge on the medium surface (floating lag time) was found to be 60sec. The time the formulation constantly floated on the dissolution medium surface (duration of floating) was evaluated to be 12hrs resulting the formation of thick gel with good floating tendency [8].

In-vitro gelling capacity:

To evaluate the formulations for their in-vitro gelling capacity by visual method, solutions of in-situ gel forming drug delivery system were prepared. The in-vitro gelling capacity of prepared formulations was measured by placing 5 ml of the gelation solution (0.1N HCL, pH 1.2) in a 15 ml borosilicate glass test tube and maintained at 37±1°C temperature. One ml of formulation solution was added with the help of pipette. The formulation was transferred in such a way that places the pipette at surface of fluid in test tube and formulation was slowly released from the pipette. As the solution comes in contact with gelation solution, it was immediately converted into stiff gel like structure. The gelling capacity of solution was evaluated on the basis of stiffness of formed gel and time period for which the formed gel remains as such. The in-vitro gelling capacity was graded in three categories on the basis of gelation time and time period for which the formed gel remains.

(+) Gels after few minutes, dispersed rapidly

(++) Gelation immediate remains for 12 hours

(+++ Gelation immediate remains for more than 12 hours

Drug content:

Preparation of standard calibration curve of

Pantoprazole: Pantoprazole (10 mg) was dissolved in (0.1 N HCl, pH 1.2) and volume was made up to 100 ml in 100 ml volumetric flask. This solution (100 mcg/ml) was further diluted with (0.1 N HCl, pH 1.2) to obtain solution of 10 to 100 mcg/ml. The absorbance of each solution was measured at 283.4 using UV spectrophotometer. The standard curve was obtained by plotting absorbance v/s. concentration (µg/ml) [9]. Ten ml of the solution was added to 900 ml (0.1N HCl, pH 1.2) Solution and stirred for 1 hr. on a magnetic stirrer. The solution was filtered, suitably diluted with (0.1N HCl, pH 1.2) and the drug concentration was determined by using a UV-visible spectrophotometer a (Shimadzu UV 1700 Pharmaspec) at 284nm against a suitable blank solution.

In-vitro release studies: An in-vitro release study was carried out using dissolution test apparatus USP Type II (Paddle Method). The following procedure was followed

throughout the study that is shown in (table 2) to determine the in vitro dissolution rate for the formulations. The release of Pantoprazole from the formulations was determined using dissolution test apparatus USP Type II with a paddle stirrer at 50 rpm. The dissolution medium used 900 ml of (0.1N HCL, pH 1.2) solution and temperature was maintained at 37 ± 0.2 °C. Ten ml of the formulation were placed into a Petri dish (4.5cm i.d.) which was kept in the dissolution vessel and 0.1N HCL solution was carefully added to the vessel avoiding any disturbance of the Petri dish. At each time interval, a precisely measured sample of the dissolution medium was pipette out and replenished with fresh medium. Pantoprazole concentration in the aliquot was determined spectrophotometrically [10].

Evaluation of in-vitro release kinetics: To study kinetics data obtained from in-vitro release were plotted in various kinetic models.

Zero-order equation:

$$\%R = Kt$$

This model represents an ideal release profile in order to achieve the pharmacological prolonged action. This is applicable to dosage forms like transdermal systems, coated forms, osmotic systems, as well as matrix tablets with low soluble drugs.

First order equation:

$$\text{Log}\% \text{ unreleased} = Kt / 2.303$$

This model is applicable to study hydrolysis kinetics and to study the release profiles of pharmaceutical dosage forms such as those containing water soluble drugs in porous matrices.

Higuchi equation:

$$\%R = Kt^{0.5}$$

This model is applicable to systems with drug dispersed in uniform swellable polymer matrix as in case of matrix tablets with water soluble drug.

Hixson and Crowell equation:

$$(\% \text{unreleased})^{1/3} = Kt$$

This expression applies to pharmaceutical dosage forms such as tablets, where the dissolution occurs in planes that are parallel to drug surface if the tablet dimensions diminish proportionality in such a manner that the initial geometrical form keeps constant all the time. When this model is used, it is assumed that release rate is limited by drug particles dissolution rate and not by diffusion that might occur through the polymeric matrix.

Korsmeyer-Peppas equation:

$$\%R = Kt^n$$

This model is widely used, when the release phenomenon could be involved. The end value could be used to characterize different release mechanisms as the model that best fits the release data is selected based on the correlation coefficient (r) value in various models. The model that gives high 'r' value is considered as the best fit of the release data. The release constant was calculated from the slope of the appropriate plots, and the regression coefficient (r²) was determined [11].

3. Results and Discussion

Determination of UV Absorbance Maxima of Pantoprazole: The standard stock solution was used to determination the max of (0.1 N HCL, pH 1.2) was used as blank for the study. The spectrum was taken between the UV range of 200-400nm. The highest peak obtained from the spectrum analysis was taken as max for Pantoprazole that used was found to be 284nm.

Identification of Drug by FTIR:

Identification study was performed using FTIR spectrophotometer. The characteristic absorption peaks of Pantoprazole were obtained at different wave numbers. The peaks obtained in the spectra of pure drug correlates with the peaks of official spectrum of British Pharmacopeia which confirms the purity of drug. The IR spectra of Pantaprazole, Sodium Alginate, Calcium Carbonate, Citric acid and its combination were shown in Fig 1-3. The following principle peaks were observed in pantaprazole as well as its combination.

- O-H and N-H (Stretching) ----3341.24 cm⁻¹
- C-H (Stretching, Vibration) ----2921.08 cm⁻¹
- N-H bending ---- 1587.87 cm⁻¹
- Skeletal Vibrations of aromatic ring-1509.93&1446.85 cm⁻¹




Figure 1: IR spectra of Pantoprazole




Figure 2: IR spectra of Sodium alginate




Figure 3: IR spectra of Pantoprazole with Excipients

Physical Appearance and pH:

All the prepared sodium alginate based in situ solution of Pantoprazole were checked for their clarity and the type of the solution. All the solutions are light brown in appearance and showed no visible particles or lumps in the preparation. After administration of the prepared solution in (0.1N HCL, pH1.2) also checked the time required for gel formation and type of gel formed. The pH was measured in each of the solution of sodium alginate based in situ solution of Pantoprazole, using a calibrated digital pH meter. The measurement of pH of data were in triplicate and the Average values given in **Table 4**. All the formulations are within required pH range suitable for absorption.

Viscosity: The viscosity of the formulations increased with an increase in sodium alginate concentration. This phenomenon is a consequence of increasing chain interaction with an increase in polymer concentration. Calcium carbonate, which is the source of cations, increased the viscosity of the formulation. This change in viscosity is due to the proportional increase in the amount of dispersed calcium carbonate. All the values are tabulated in the table 5. The increase in order of viscosity was observed form which F6 shown the higher viscosity value and the order of increase of formulations is as **F1<F2<F3<F4<F5<F6**.

Floating Behavior: The buoyancy lag time varied with the formulation variables. Formulation F6 exhibited the least buoyancy lag time (70 s) while formulation F2 exhibited the highest lag time (82 s). The decrease in the buoyancy lag time of a formulation F6 can be attributed to the availability of an increased the concentration of calcium carbonate, being entrapped in the formed gel to give rapid buoyancy. Irrespective of formulation variables, buoyancy duration was > 12 hours.

Gelling Capacity: In vitro gelling capacity of various formulation of in-situ floating gel is reported in table 9. All the formulations were suitable to produce gel and their gelling capacity lasted for about longer than 8 hrs and lasted upto 24 hrs which indicated as >12 hrs. The concentration of sodium alginate lead to increase in its swelling capacity and calcium carbonate a cross linking agent to cations in the solution made to be material sticky and viscous for the longer period of time.

Determination of Calibration Curve: The calibration curve obtained by following the specified procedure has given the satisfied fitting value given as regression value R= 0.9997 which followed straight line equation $y=mc+c$.




Figure 4: Calibration Curve of Pantoprazole

In-Vitro Drug Release:

The in-vitro drug releases of the in situ floating gel were carried in (0.1N HCl, 1.2 pH) solution from 0 to 12 hrs by using dissolution test apparatus USP Type II (Paddle Method). The samples were withdrawn at different time intervals and analyzed at 284 nm. Percentage Cumulative drug release was calculated on the basis of mean amount of Pantoprazole present in the respective solution. The results obtained in the in vitro drug release for the formulations F1 to F6 in (Table 11). The plots are shown in (Figure no. 9) for % cumulative drug release VS time. Formulation F1, F2, F3, F4, F5 and F6 released about 93.01 %, 97.60 %, 98.56%, 96.68%, 97.92% ,98.88 of drug after 12 hrs. respectively. The results are shown in Table 10 indicate that the formulation, F6 which was prepared by the Sodium alginate (2%) with Pantoprazole showed drug release evenly and completely upto 12 hrs. Thus, the formulation (F6) has better result as comparison to others formulations as sustained release.




Figure 5: In-vitro Release Profile of Pantoprazole (F1 To F6)

Release Kinetics: The % cumulative drug release (%CDR) was calculated. The data obtained was further subjected to PCP DISSO software for curve fitting for drug release data. The best fit model was found to be First order and Krosmeysers peppas with the regression in the range of 0.4755 – 0.4998 and 0.9532-0.9969 and the formulation exhibited fickinian diffusion mechanism with a value of 0.1095-0.1609. Formulation F6 exhibited required release characteristics with the regression value of 0.9969, as show in table 11. The F6 formulation was further subjected to accelerated stability study.

4. Conclusion

The present work was carried out to develop a novel in situ gum based drug delivery. The methodology adopted for preparation of in-situ gel solution was very simple and cost effective. It is newer approach to improve easy instillation, residence time and bioavailability and prolong drug release. From the study conducted, the following conclusions were drawn, by varying the concentration of polymer, it is to obtain the increased residence time and sustained drug release. Among the novel gum systems used sodium alginate was found to be best gum and viscosity enhancer in combination with polymers with respect to increased duration of action and drug release. The study revealed that

an appropriate concentration is an important factor in achieving increased duration of action and also release from the dosage form to achieve sustained effect. The gel formed in situ afforded sustained drug release over 8 hrs periods. The formulations exhibited therapeutic efficacy. The

developed formulation is a viable alternative conventional solution by virtue of its ability to enhance bioavailability through its longer gastric residence time and ability to sustain drug release.

Table 1: Composition of Floating in situ gel

Ingredients	Formulation code & Quantities					
	F1	F2	F3	F4	F5	F6
Pantoprazole	400mg	400mg	400mg	400mg	400mg	400mg
Sodium Alginate	1gm	2 gm	3 gm	1 gm	2 gm	3 gm
Sodium Citrate	250 mg	250 mg	250 mg	500 mg	500 mg	500 mg
CaCO ₃	250 mg	250 mg	250 mg	500 mg	500 mg	500 mg
D. Sorbitol	1gm	1gm	1 gm	1gm	1 m	1 gm
Distil Water	q.s.	q.s.	q.s.	q.s.	q.s.	q.s.
Total Weight(ml)	100ml	100ml	100ml	100ml	100ml	100ml

Table 2: Dissolution of Floating in Situ Gel

Dissolution medium	900 ml of (0.1N HCL, 1.2 pH) solution
Temperature	37 °C±0.2 °C
RPM	50
Volume withdrawn	10 ml every 1 hrs.
_{max}	284nm
Sol. taken	Ten ml sol. (Known drug content)

Table 3

N	Mechanism
0.5	Fickian diffusion(Higuchi matrix)
0.5<n<1	Anomalous transport
1	Case- II transport(zero order release)
n>1	Super case- II transport

Table 4: p^H of prepared In-situ gel formulation (x ± S.D)

Formulation code	F1	F2	F3	F4	F5	F6
p ^H	9.3±0.11	9.2±0.47	8.9±0.28	9.4±0.36	9.2±0.34	8.9±0.22

All the values are mean of 3 and S.D

Table 5: Viscosity of prepared in-situ gel formulation (x ± S.D)

Formulation code	F1	F2	F3	F4	F5	F6
Viscosity	91±0.29	132±0.58	156±0.63	192±0.52	221±0.62	243±0.18

Table 6: Floating behavior of prepared In-situ gel formulation (x ± S.D)

Formulation code	F1	F2	F3	F4	F5	F6
Floating lag time(sec)	72±0.35	82±0.41	74±0.56	76±0.09	72±0.83	70±0.24
Floating time (hr)	10	>10	>10	>10	>12	>12

Table 7: Gelling capacity of prepared In-situ gel formulation

Formulation code	F1	F2	F3	F4	F5	F6
Gelling capacity	++	++	++	++	+++	+++

Table 8: Results of Calibration Curve of Pantoprazole

Date :		08.02.2016				
Calibration curve for :		Pantoprazole				
Solvent / Mobile Phase :		0.1N HCL				
Wavelength (nm) :		284				

Unit for Concentration :	mcg/ml					
Analytical Response :	0					
Done By :	R					
Equation for the standard curve :		Conc. =	45.48	0	+	0.088
		R =	0.9997			

Table 9: Results of Drug Content of all formulation of Pantoprazole

Formulation code	F1	F2	F3	F4	F5	F6
Content uniformity (%)*	97.03±0.38	98.03±0.38	98.54±0.40	97.08±0.40	98.09±0.42	98.62±0.42

Table 10: In-Vitro Drug release of Pantoprazole *in-situ* gel Formulations (F1- F6)

S.No	Time	%R1	%R2	%R3	%R4	%R5	%R6
1	0	0.00	0.00	0.00	0.00	0.00	0.00
2	30	24.82	25.90	27.72	26.21	26.83	28.60
3	60	35.31	36.33	37.33	36.13	36.61	39.13
4	120	46.71	47.95	48.84	48.11	48.39	49.71
5	180	59.62	60.92	61.38	60.14	61.46	61.44
6	240	63.01	63.69	64.91	63.55	64.45	65.17
7	300	75.91	76.35	77.51	76.07	77.53	79.00
8	360	84.34	79.37	80.42	84.63	80.34	80.89
9	420	93.56	81.39	82.55	94.40	82.40	83.87
10	480	93.02	96.72	90.98	94.39	85.30	86.93
11	540	93.43	97.07	98.24	96.37	97.39	90.72
12	600	93.91	97.60	98.56	96.68	97.92	98.88

Table 11: Release Kinetics of all prepared formulations

Model		F1	F2	F3	F4	F5	F6
Zero order	K	0.0812	0.0745	0.0693	0.0834	0.0912	0.0939
	R	0.4523	0.4326	0.4122	0.4643	0.4851	0.4932
First order	K	-0.006	0.0124	-0.008	0.2321	-0.009	-0.009
	R	0.4755	0.4852	0.4672	0.4912	0.4936	0.4998
Higuchi	K	0.2322	0.2125	0.1913	0.1956	0.1817	0.2071
	R	0.9121	0.8856	0.9190	0.8952	0.9021	0.8725
Hixon Crowell	K	-0.0002	-0.0003	-0.0006	0.0123	0.0011	-0.0003
	R	0.5236	0.4875	0.4232	0.5189	0.4758	0.4758
Krosmeyer – Peppas	K	0.2456	0.2836	0.2925	0.2268	0.2861	0.3411
	n	0.1612	0.1324	0.1248	0.1536	0.1600	0.1274
	R	0.9532	0.9658	0.9875	0.9647	0.9855	0.9969

5. References

[1] Jun Chen, William E, Blevins, Haesun Park, Kinam Park. Gastric retention properties of super-porous hydrogel composites. *J Control Releases*. 2000; 64: 39-51.111

[2] Kouichi Nakamichi, Hiroyuki Yasuura, Hiroshi Fukui, Masaaki Oka, Syougo Izumi. Evaluation of a floating dosage form of nicardipine hydrochloride and HPMC acetate succinate prepared using a twinscrew extruder. *Int J Pharm*. 2001; 218: 103-112.

[3] Shashi Kiran Mishra Kamla Pathak. Formulation and evaluation of oil entrapped gastro retentive floating gel beads of loratadine. *Acta Pharm*. 2008, 58:187-197

[4] Durga Jaiswal, Arundhati Bhattacharya, Indranil Kumar Yadav, HariPratap Singh, Dinesh Chandra and D.A. Jain. Formulation And Evaluation Of Oil Entrapped Floating Alginate Beads Of Ranitidine Hydrochloride. *Int. J. Pharm. Pharm.sci*. Nov.-Dec. 2009;1:128-140

[5] Rammohan Bera, Bivash Mandal, Manas Bhowmik, Hriday Bera, Sanjoy K. Dey, Gouranga Nandi, Lakshmi K. Ghosh. Formulation and In Vitro Evaluation of Sunflower Oil Entrapped within Buoyant Beads of Furosemide. *Sci Pharm*. 2009; 77; 669-678

[6] V. Iannuccelli, G. Coppi, M.T. Bernabei, R. Cameroni. Air compartment multiple-unit system for prolonged gastric residence. Part I. Formulation study. *IntJ Pharma*1998;174: 47-54

[7] P.L. Bardonneta, b, V. Faivre a,, W.J. Pugh c, J.C. Piffaretti d, F. Falson. Gastro retentive dosage forms: Overview and special case of Helicobacter pylori. *J. controll Release* 2006;111: 1 – 18

- [8] Parauvathanahalli Siddalingam, Rajniknith, Brahmeshwar Mishra. Preparation and in vitro-characterization of gellan based floating beads of acetohydroxamic acid for eradication of H. Pylori. *Acta Pharm.* 2007;57: 413–427
- [9] Pornsak Sriamornsaka, Nartaya Thirawonga, Satit Puttipipatkachorn. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: effect of some additives, hardening agent or coating on release behavior of metronidazole. *Eur J. Pharm. Sci.* 2005;24: 363–373
- [10] Pornsak Sriamornsak, Srisagul Sungthongjeen, Satit Puttipipatkachorn. Use of pectin as a carrier for intragastric floating drug delivery: Carbonate salt contained beads. *Carbohydrate Polymers* 2007; 67: 436–445.
- [11] Hari BN et al. Floating Drug Delivery of 5-Fluorouracil as Gastro retentive System *J Young Pharma* 2010 Oct-Dec ; 2(4) : 350-355.